FY2024 EPS Estimates for OPKO Health, Inc. (NASDAQ:OPK) Cut by Barrington Research

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Barrington Research reduced their FY2024 EPS estimates for shares of OPKO Health in a research note issued to investors on Wednesday, May 8th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will post earnings per share of ($0.34) for the year, down from their prior estimate of ($0.29). Barrington Research has a “Outperform” rating and a $1.50 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. Barrington Research also issued estimates for OPKO Health’s Q4 2024 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at ($0.02) EPS.

OPK has been the topic of several other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a report on Monday, April 1st. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday.

OPKO Health Stock Performance

OPK opened at $1.26 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15. The company has a market cap of $878.21 million, a price-to-earnings ratio of -5.04 and a beta of 1.81. The company’s 50 day moving average is $1.15 and its 200 day moving average is $1.22. OPKO Health has a 12-month low of $0.85 and a 12-month high of $2.24.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $182.99 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business’s quarterly revenue was down 26.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPK. Swiss National Bank increased its holdings in OPKO Health by 1.0% in the third quarter. Swiss National Bank now owns 934,055 shares of the biotechnology company’s stock valued at $1,494,000 after buying an additional 8,800 shares in the last quarter. Van ECK Associates Corp increased its holdings in OPKO Health by 6.8% in the third quarter. Van ECK Associates Corp now owns 150,771 shares of the biotechnology company’s stock valued at $241,000 after buying an additional 9,591 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in OPKO Health by 30.0% in the third quarter. Levin Capital Strategies L.P. now owns 65,000 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 15,000 shares in the last quarter. Principal Financial Group Inc. increased its holdings in OPKO Health by 39.1% in the third quarter. Principal Financial Group Inc. now owns 59,566 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 16,733 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its holdings in OPKO Health by 140.3% in the third quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 18,041 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were bought at an average cost of $0.99 per share, with a total value of $495,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 208,868,225 shares in the company, valued at approximately $206,779,542.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired a total of 3,100,000 shares of company stock valued at $2,923,000 over the last ninety days. 47.26% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.